

Global TransBiotech, Inc.



Any offering to accredited investors is speculative and involves high risks, including lack of investment liquidity, expected dilution, current lack of profitability, relatively high levels of long term debt and intense competition within the industry, among others.

Global TransBiotech, Inc., a U.S. development stage biotech company headquartered in Monterey Park, California, focuses its business on in-licensing post-discovery technologies and product leads, developing these projects to achieve predefined value enhancing milestones, and out-licensing them to pharmaceutical and biotech companies for further development and commercialization. The company expects to locate most operations in Taiwan, through subsidiaries responsible for evaluation, verification and development of specific projects. By undertaking development in Taiwan, the company expects to generate cost savings of 50-70% as compared to similar projects in the U.S. or Europe, leveraging the cost arbitrage into greater returns for investors.

The company is focusing its in-licensing activities in the three areas: pharmaceuticals, including drugs and biologicals; medical devices for treatment and diagnostics; and green industry technologies for use in agriculture and energy. Currently, the company has 17 product leads under evaluation: 10 therapeutics, 6 medical devices, and 1 green technology. The company expects its growing product pipeline to result in four out-licensed projects in four years.

The company's founders, management team, advisors and consultants form an extensive experienced network with contacts at professional associations, academic and technology research institutions, biotech and pharmaceutical companies, as well as venture capital firms, which are expected to yield financing sources, in-license product leads and out-license opportunities.

The company's asset appreciation business model has the potential to earn both shorter term upfront revenues and milestone payments, as well as longer term returns in form of royalties.

INCOME STATEMENT HIGHLIGHTS

Global TransBiotech, Inc. is a private company and does not disclose financials without confidentiality agreement.

BALANCE SHEET HIGHLIGHTS

Global TransBiotech, Inc. is a private company and does not disclose financials without confidentiality agreement.

FOCUS PRODUCTS

HemaVax

A hematological and immunological adjuvant based on a protein naturally produced within the human body developed for cancer therapy that accompanies a primary cancer modality, such as radiation therapy, chemotherapy or cancer-related surgery.

Thermal Strip Thermocycler (dtPCR™)


A credit card size self-contained disposable thermocycler and detection device on which rapid polymerase chain reaction (PCR) tests are being adapted for medical diagnostics, biological warfare agent detection, life science research tools, and other industrial applications.

Green Biocontrol Products

A series of environmental-friendly plant oil-based products to target: dust mite (for asthma), mosquitoes and larva (for Dengue fever), crawling insects, such as cockroaches and ants (for household), snails (for agriculture), and other applications.

HEADQUARTERS

Global TransBiotech, Inc.
 1111 Corporate Center Drive, Suite 205
 Monterey Park, CA 91754
 Phone: 626-443-0582 Fax: 626-454-5750
 Hun-Chi Lin, Ph.D., CEO
 Email: hunchi.lin@myhealth.com



The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. For complete disclaimer information, the reader is hereby referred to the Disclaimer Page of the Flaherty Financial News / WallStreet Research Small Cap Conference Book or the www.WallStreetResearch.org website.